2022-09-30 Psychedelic Chronicle

Tryp Therapeutics Add 2 New Provisional Patents to Intellectual Property Portfolio

Recently, clinical-stage psychedelic biotechnology company Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) filed for two new provisional patents strengthening the company’s intellectual property portfolio. The company which focuses on developing psilocybin-based medicines for illnesses with unmet medical needs announced the 2 patents via press release. The first #63/405,786 is a patent application for the use of psilocybin to treat patients with fibromyalgia while the other patent, #63/375,305 expands the intellectual property related to the company’s development of TRP-8803. About Tryp Therapeutics Tryp Therapeutics is a cutting-edge biotechnology company that is focused on developing molecules related to psilocybin to treat diseases The post Tryp Therapeutics Add 2 New Provisional Patents to Intellectual Property Portfolio appeared first on Psychedelic Chronicle.

External link. We are not responsible for the content.

Read more ↗

More From Psychedelic Chronicle

2023-02-16 Psychedelic Chronicle

Choose Ketamine Complete Capital Raise to Expand Technology Platform

In a major milestone for mental health care, Austin-based Choose Your Horizon Inc., also known as Choose Ketamine, ha...

2022-10-14 Psychedelic Chronicle

Biomind Labs Secure FDA Pre-IND Meeting for Feedback on NCE Triptax

The well-known psychedelic biotech company Biomind Labs Inc. (NEO: BMND) (OTC: BMNDF) (FSE: 3XI) announced that it ha...

2022-10-11 Psychedelic Chronicle

Silo Pharma Initiate Toxicity Study of Ketamine Formulation for Fibromyalgia Treatment

Silo Pharma (Nasdaq: SILO), a developmental-stage psychedelic biopharmaceutical firm, announced today that it has beg...

Latest News

2026-09-04 The Microdose (Berkeley)

A federal report encourages states to prepare for FDA approval of psychedelics; Could THC help with the psychedelic blinding problem?

Plus: Ketamine seized at the UK border hits record high; an Arizona ibogaine trial; Study reveals cell signaling that...

2026-09-04 The Psychedelic Blog (Substack)

7 Questions I'm Obsessed With About Psychedelics Right Now

Welcome to The Psychedelic Blog. An independent media platform covering drugs, altered states & the culture surroundi...

2026-09-04 DoubleBlind Magazine

Is “Gas Station Molly” the Next Big Grey Market Drug?

It feels like MDMA, skips the comedown, and it's already on head shop shelves. But is it legal? [...] Read More... Th...

2026-09-04 Psychedelic Press (Substack)

Scent, Ritual, and Altered States

Kamila Aubre explores scent and the psychedelic experience

2026-09-02 DoubleBlind Magazine

Inside the First Ayahuasca Forum Hosted by Indigenous Peoples

100 Indigenous leaders will gather at the World Ayahuasca Forum to set the terms for ayahuasca's future. [...] Read M...

2026-09-01 DoubleBlind Magazine

Can Psilocybin Protect Skin Cells From Premature Aging?

PLUS Carlos Castaneda, foraging for psilocybin mushrooms, and Resilient Pharmaceuticals. [...] Read More... The post ...